Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100

CONCLUSIONS: This exploratory analysis in advanced ROC did not find evidence for associations between gene expression signatures and outcomes of pembrolizumab. mIHC analysis suggests CD11c+ and CD11c+/MHCII-/CD163-/CD68- phenotypes representing myeloid cell populations may be associated with improved outcomes with pembrolizumab in advanced ROC.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02674061.PMID:37862791 | DOI:10.1016/j.ygyno.2023.09.012

Source: Methods of Information in Medicine - October 20, 2023 Category: Information Technology Authors: Jonathan A Ledermann Ronnie Shapira-Frommer Alessandro D Santin Alla S Lisyanskaya Sandro Pignata Ignace Vergote Francesco Raspagliesi Gabe S Sonke Michael Birrer Diane M Provencher Jalid Sehouli Nicoletta Colombo Antonio Gonz ález-Martín Ana Oaknin P B Source Type: research